Search

Displaying results 2131 - 2140 of 9325 in total
  1. Drug

    Tranexamic acid

    go.drugbank.com/drugs/DB00302
    ApprovedInvestigational

    It possesses a similar mechanism of action to [aminocaproic acid] but is approximately 10-fold more potent. … Tranexamic acid is a synthetic derivative of [lysine] used as an antifibrinolytic in the treatment and prevention of major bleeding.

    Products: ZYEX-T, HEAMIC-T (Tranexamic Acid Injection 100mg/mL)
  2. Drug

    Aprocitentan

    go.drugbank.com/drugs/DB15059
    ApprovedInvestigational

    [L50261] It was the first antihypertensive employing a novel mechanism to be approved in almost 40 years.[L50261] … It is the active metabolite of [macitentan].

  3. Drug

    Sacubitril

    go.drugbank.com/drugs/DB09292
    ApprovedInvestigational

    It was approved by the FDA after being given the status of priority review for on July 7, 2015. … Sacubitril is a prodrug neprilysin inhibitor used in combination with valsartan to reduce the risk of cardiovascular events in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection

  4. Drug

    Benralizumab

    go.drugbank.com/drugs/DB12023
    ApprovedInvestigational

    [A31294] It inhibits the binding of IL-5 as well as the hetero-oligomerization of the alpha and beta subunits of the IL-5R, thus blocking signal transduction. … Benralizumab is a humanized recombinant monoclonal antibody of the isotype IgG1k immunoglobulin that specifically binds to the alpha chain of the interleukin 5 receptor (IL-5R) expressed on eosinophils

  5. Drug

    Lorlatinib

    go.drugbank.com/drugs/DB12130
    ApprovedInvestigational

    It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to … Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer[L39905] which was first approved by the US FDA in November of 2018

  6. Drug

    Barley malt

    go.drugbank.com/drugs/DB10980
    Approved

    Barley malt allergenic extract is used in allergenic testing.

    Mixtures: Immune Essence to Prolong Life, Immune Essence to Prolong Life
  7. Drug

    Dihydrotachysterol

    go.drugbank.com/drugs/DB01070
    ApprovedWithdrawn

    A vitamin D that can be regarded as a reduction product of vitamin D2.

  8. Drug

    Salmon calcitonin

    go.drugbank.com/drugs/DB00017
    ApprovedInvestigational

    Synthetic peptide, 32 residues long formulated as a nasal spray.

  9. Drug

    Antilymphocyte immunoglobulin (horse)

    go.drugbank.com/drugs/DB09312
    ApprovedInvestigational

    The result is polyclonal IgG that is then purified from the horse's serum to produce a usable drug product that can be used for immunosuppression. … Equine ATG is currently indicated for the suppression of the immune system to prevent renal transplant rejection and in the treatment of aplastic anemia.

    Categories: Increased T Lymphocyte DestructionSynonyms: e-ATG
  10. Drug

    Zuranolone

    go.drugbank.com/drugs/DB15490
    ApprovedInvestigational

    binding to a non-benzodiazepine site on the receptor. … [A260791] Zuranolone was approved by the FDA on August 4th, 2023, and it is currently the only approved treatment for women with postpartum depression.